[Pharmacotherapy in the treatment of obesity].
Currently, the substances orlistat and sibutramine are approved drugs for the pharmacotherapy of obesity. Used in combination with increased exercise and dietary measures, both are capable of significantly reducing weight. In the USA and Europe, official approval for the selective cannabinoid receptor antagonist, rimonabant has been applied for.
Hamann
Andreas
A
Diabetes-Klinik Bad Nauheim und Abtei- lung Innere Medizin I, Universitätsklinikum Heidelberg. a.hamann.diabetes@pitzer-kliniken.de
D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D063387:Cannabinoid Receptor Antagonists; D002986:Clinical Trials as Topic; D003503:Cyclobutanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015444:Exercise; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000627:therapeutic use*; D008049:Lipase / Q000037:antagonists & inhibitors; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy*; D000077403:Orlistat; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use; D000077285:Rimonabant; D013997:Time Factors; D015431:Weight Loss
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D063387:Cannabinoid Receptor Antagonists; D003503:Cyclobutanes; D004791:Enzyme Inhibitors; D007783:Lactones; D010880:Piperidines; D011720:Pyrazoles; D000077403:Orlistat; D008049:Lipase; D000077285:Rimonabant; C058254:sibutramine